CNS Stimulants and Wake-Promoting Agents
All stimulants probe catecholamine deficiency. This section covers modafinil, methylphenidate, amphetamines, solriamfetol, pitolisant, and caffeine — their differences in mechanism, selectivity, and safety create a diagnostic hierarchy. All are symptom management; none address root cause.
1 CNS Stimulants and Wake-Promoting Agents
All stimulants probe catecholamine (dopamine/norepinephrine) deficiency. Their differences in mechanism, selectivity, and safety create a hierarchy. All are symptom management — none address root cause. Hierarchy from safest to most concerning: pitolisant > solriamfetol ≈ modafinil > methylphenidate > amphetamines.
1.1 If stimulants work
Drug increased dopamine/norepinephrine → cognition improved → signaling was inadequate.
- Certainty
- Medium — CSF catecholamine reduction documented (Walitt et al. 2024); stimulant surveys 77.1% brain fog improvement (Eckey et al. 2025); methylphenidate RCT 17% response (Blockmans et al. 2006); solriamfetol RCT significant fatigue improvement (p=0.039) (Young et al. 2025). But effect sizes modest and survey data uncontrolled.
- Does NOT tell us
- why catecholamines are deficient; whether benefit is sustainable (masking fatigue enables overexertion — PNAS: +77.1% brain fog but −1.5% PEM).
- Action
- catecholamine involvement confirmed; combine with LDN (neuroinflammation) or mitochondrial supplements (metabolic constraint) to identify upstream cause.
- Level of action
- Symptom management — stimulants compensate for deficient signaling without restoring production or removing inflammatory precursor depletion.
Reuptake blocker works but amphetamines cause severe crashes → low-production deficiency (stores depleted, production insufficient to replenish).
- Certainty
- Low to Medium.
- Level of action
- Symptom management.
Modafinil has brain ATP enhancement and M1→M2 microglial shift (Minzenberg and Carter 2008). Methylphenidate increases REE +7% and chronically decreases hippocampal ATP (Graveling et al. 2024). Modafinil tolerated + methylphenidate worsens energy → brain can benefit from ATP enhancement but cannot tolerate +7% metabolic cost.
- Certainty
- Low (modafinil’s only ME/CFS RCT was negative, n=14 (Randall et al. 2005)).
- Level of action
- Symptom management — modafinil blurs toward partial root cause (brain-level, speculative).
Pitolisant blocks H3 autoreceptors, increasing endogenous histamine. Works without sympathetic activation → histaminergic pathway functional.
- Certainty
- Low — no ME/CFS data.
- Level of action
- Partial root cause (speculative) — anti-neuroinflammatory M1→M2 microglial shift.
1.2 What a positive response does NOT reveal
A positive stimulant response confirms that catecholamine signaling was insufficient but does not reveal why the catecholamines are deficient (neuroinflammatory precursor depletion, metabolic packaging failure, or genetic causes remain indistinguishable). Critically, it does not tell us whether the benefit is sustainable: stimulants can mask fatigue and enable overexertion, and the same survey showing +77.1% brain fog improvement showed −1.5% PEM (worsening). Because effect sizes are modest and much of the supporting data is uncontrolled survey data, a genuine effect cannot be cleanly separated from placebo.
1.3 If stimulants do NOT work
- Catecholamine deficiency may not be present — cognitive dysfunction from glymphatic failure, direct cytokines, cerebral hypoperfusion, or neuronal mitochondrial failure.
- Receptors downregulated — chronic inflammation reduces expression.
- Side effects mask benefit — sympathetic activation, metabolic cost, sleep disruption produce net negative effect.
1.4 Key caveat
A positive response is not automatically beneficial. Stimulants mask fatigue, which enables overexertion — the PNAS survey showed +77.1% brain fog improvement but −1.5% PEM (worsening). Monitor PEM closely. Stimulants are contraindicated in the absence of objective activity monitoring, because subjective improvement can conceal an increasing physiological deficit.
1.5 How Stimulants combine with other medications
- Stimulant works but PEM worsens → the critical warning: catecholamine deficit is downstream of energy deficit. Discontinue or strictly dose-limit with objective activity monitoring.
- Methylphenidate does not work + LDA works → common ME/CFS pattern: receptor-level support more effective than reuptake blockade.
- Stimulant works + LDA works → severe dopamine deficit requiring maximal pharmacological support. Prioritize treating upstream cause.
1.6 Compendium
The full pharmacodiagnostic entries — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Methylphenidate entry, Modafinil/Armodafinil entry, and related stimulant entries).